“Excessive Daytime Sleepiness Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Excessive Daytime Sleepiness Market.
The Excessive Daytime Sleepiness Pipeline report embraces in-depth commercial, regulatory, and Excessive Daytime Sleepiness clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Excessive Daytime Sleepiness drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
The report provides insights into:
The report provides detailed insights into the emerging therapies for Excessive Daytime Sleepiness treatment and the aggregate therapies developed by major pharma companies.
It accesses the different Excessive Daytime Sleepiness therapies segmented into early-stage, mid-stage, and late-stage of clinical development.
It outlines the major Excessive Daytime Sleepiness companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the Excessive Daytime Sleepiness drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Excessive Daytime Sleepiness therapeutic market.
Analysis of Emerging Excessive Daytime Sleepiness Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Excessive Daytime Sleepiness pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Learn How the Excessive Daytime Sleepiness Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @
Excessive Daytime Sleepiness Therapeutics Landscape
There are approx. 10+ key companies developing therapies for Excessive Daytime Sleepiness. Currently, Balance Therapeutic is leading the therapeutics market with its Excessive Daytime Sleepiness drug candidates in the most advanced stage of clinical development.
Excessive Daytime Sleepiness Companies Actively Working in the Therapeutic Market Include:
Benevolent AI Bio
And Many Others
Emerging and Marketed Excessive Daytime Sleepiness Drugs Covered in the Report Include:
Pentetrazol: Balance Therapeutics
Balance Therapeutics’ lead drug candidate, Pentetrazol is a small molecule in development for the treatment of excessive daytime sleepiness due to narcolepsy. The drug has demonstrated good efficacy in its Phase I clinical trials. The drug is a CNS (central nervous system) convulsant that binds to the picrotoxin site of GABA (A) receptor.
TAK 925: Takeda Pharmaceuticals
Takeda’s “breakthrough” drug TAK 925 is currently being evaluated for the treatment of excessive daytime sleepiness due to hypersomnia as well as narcolepsy. The drug has been designated with orphan drug status for narcolepsy. It is an orexin receptor type-2 agonist which plays an important role in the regulation of sleep and wakefulness.
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Excessive Daytime Sleepiness Companies Working in the Market @
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Excessive Daytime Sleepiness Treatment Patterns
4. Excessive Daytime Sleepiness – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Excessive Daytime Sleepiness Late Stage Products (Phase-III)
7. Excessive Daytime Sleepiness Mid-Stage Products (Phase-II)
8. Excessive Daytime Sleepiness Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Excessive Daytime Sleepiness Discontinued Products
13. Excessive Daytime Sleepiness Product Profiles
14. Major Excessive Daytime Sleepiness Companies in the Market
15. Key Products in the Excessive Daytime Sleepiness Therapeutics Segment
16. Dormant and Discontinued Products
17. Excessive Daytime Sleepiness Unmet Needs
18. Excessive Daytime Sleepiness Future Perspectives
19. Excessive Daytime Sleepiness Analyst Review
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
“Extracorporeal Circulation System Market Insight, Competitive Landscape, and Market Forecast, 2028” report delivers an in-depth understanding of historical and forecasted Extracorporeal Circulation System market size, share, and trends globally, which comprises North America, Europe, APAC, and RoW. Moreover, it covers the key companies, emerging products, and commercial & regulatory development, in the Extracorporeal Circulation System Market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States